Tumor necrosis factor-α is a potent acth secretagogue

Comparison to interleukin-1β

Burt Sharp, Shannon G. Matta, Phillip K. Peterson, Robert Newton, Chun Chao, Kathy McAllen

Research output: Contribution to journalArticle

199 Citations (Scopus)

Abstract

Tumor necrosis factor-α (TNF) and interleukin-1 β (IL-1) are secreted by activated monocytes and other immune cells. Since IL-1 has been shown to elevate rat plasma ACTH and both of these cytokines induce similar acute-phase responses, the present studies of TNF were undertaken to characterize the ACTH response to this immune cell product. Human rTNF, administered iv at doses (100-1000 ng) which failed to affect blood pressure, food consumption or prolactin levels, resulted in significant peak elevations of rat plasma ACTH within 20 min (mean ± SE 304+94 and 958 ± 128 pg/ml for 100 and 1000 ng, respectively, compared to 53 ± 16 pg/ml for vehicle). rTNF from two different sources produced similar elevations of ACTH as an equivalent amount of rIL-1. TNF failed to affect cultured anterior pituicytes, and it did not modify the response to CRF. When administered into the upper third cerebroventricle, TNF 20 ng failed to affect ACTH levels whereas IL-1 30 ng raised ACTH to 638 ± 79 pg/ml compared to 177 ± 24 pg/ml for vehicle (p ≪ 0.001). Furthermore, intraparenchymal injection of IL-1, directly above the median eminence, elevated ACTH to 484 ± 93 pg/ml; again, TNF was completely ineffective. Thus, TNF-α and IL-1β are both potent ACTH secretagogues with complementary modes of action; however, the proximate target of TNF action appears to be peripheral to the CNS and pituitary whereas that of IL-1 appears to be the median eminence.

Original languageEnglish (US)
Pages (from-to)3131-3133
Number of pages3
JournalEndocrinology
Volume124
Issue number6
DOIs
StatePublished - Jan 1 1989

Fingerprint

Interleukin-1
Adrenocorticotropic Hormone
Tumor Necrosis Factor-alpha
Median Eminence
Acute-Phase Reaction
Prolactin
Monocytes
Cytokines
Blood Pressure
Food
Injections

All Science Journal Classification (ASJC) codes

  • Endocrinology

Cite this

Sharp, B., Matta, S. G., Peterson, P. K., Newton, R., Chao, C., & McAllen, K. (1989). Tumor necrosis factor-α is a potent acth secretagogue: Comparison to interleukin-1β. Endocrinology, 124(6), 3131-3133. https://doi.org/10.1210/endo-124-6-3131

Tumor necrosis factor-α is a potent acth secretagogue : Comparison to interleukin-1β. / Sharp, Burt; Matta, Shannon G.; Peterson, Phillip K.; Newton, Robert; Chao, Chun; McAllen, Kathy.

In: Endocrinology, Vol. 124, No. 6, 01.01.1989, p. 3131-3133.

Research output: Contribution to journalArticle

Sharp, B, Matta, SG, Peterson, PK, Newton, R, Chao, C & McAllen, K 1989, 'Tumor necrosis factor-α is a potent acth secretagogue: Comparison to interleukin-1β', Endocrinology, vol. 124, no. 6, pp. 3131-3133. https://doi.org/10.1210/endo-124-6-3131
Sharp, Burt ; Matta, Shannon G. ; Peterson, Phillip K. ; Newton, Robert ; Chao, Chun ; McAllen, Kathy. / Tumor necrosis factor-α is a potent acth secretagogue : Comparison to interleukin-1β. In: Endocrinology. 1989 ; Vol. 124, No. 6. pp. 3131-3133.
@article{f3604bc9e2034a4087eee0a735081f2c,
title = "Tumor necrosis factor-α is a potent acth secretagogue: Comparison to interleukin-1β",
abstract = "Tumor necrosis factor-{\^I}± (TNF) and interleukin-1 β (IL-1) are secreted by activated monocytes and other immune cells. Since IL-1 has been shown to elevate rat plasma ACTH and both of these cytokines induce similar acute-phase responses, the present studies of TNF were undertaken to characterize the ACTH response to this immune cell product. Human rTNF, administered iv at doses (100-1000 ng) which failed to affect blood pressure, food consumption or prolactin levels, resulted in significant peak elevations of rat plasma ACTH within 20 min (mean {\^A}± SE 304+94 and 958 ± 128 pg/ml for 100 and 1000 ng, respectively, compared to 53 ± 16 pg/ml for vehicle). rTNF from two different sources produced similar elevations of ACTH as an equivalent amount of rIL-1. TNF failed to affect cultured anterior pituicytes, and it did not modify the response to CRF. When administered into the upper third cerebroventricle, TNF 20 ng failed to affect ACTH levels whereas IL-1 30 ng raised ACTH to 638 ± 79 pg/ml compared to 177 ± 24 pg/ml for vehicle (p ≪ 0.001). Furthermore, intraparenchymal injection of IL-1, directly above the median eminence, elevated ACTH to 484 ± 93 pg/ml; again, TNF was completely ineffective. Thus, TNF-{\^I}± and IL-1β are both potent ACTH secretagogues with complementary modes of action; however, the proximate target of TNF action appears to be peripheral to the CNS and pituitary whereas that of IL-1 appears to be the median eminence.",
author = "Burt Sharp and Matta, {Shannon G.} and Peterson, {Phillip K.} and Robert Newton and Chun Chao and Kathy McAllen",
year = "1989",
month = "1",
day = "1",
doi = "10.1210/endo-124-6-3131",
language = "English (US)",
volume = "124",
pages = "3131--3133",
journal = "Endocrinology",
issn = "0013-7227",
publisher = "The Endocrine Society",
number = "6",

}

TY - JOUR

T1 - Tumor necrosis factor-α is a potent acth secretagogue

T2 - Comparison to interleukin-1β

AU - Sharp, Burt

AU - Matta, Shannon G.

AU - Peterson, Phillip K.

AU - Newton, Robert

AU - Chao, Chun

AU - McAllen, Kathy

PY - 1989/1/1

Y1 - 1989/1/1

N2 - Tumor necrosis factor-α (TNF) and interleukin-1 β (IL-1) are secreted by activated monocytes and other immune cells. Since IL-1 has been shown to elevate rat plasma ACTH and both of these cytokines induce similar acute-phase responses, the present studies of TNF were undertaken to characterize the ACTH response to this immune cell product. Human rTNF, administered iv at doses (100-1000 ng) which failed to affect blood pressure, food consumption or prolactin levels, resulted in significant peak elevations of rat plasma ACTH within 20 min (mean ± SE 304+94 and 958 ± 128 pg/ml for 100 and 1000 ng, respectively, compared to 53 ± 16 pg/ml for vehicle). rTNF from two different sources produced similar elevations of ACTH as an equivalent amount of rIL-1. TNF failed to affect cultured anterior pituicytes, and it did not modify the response to CRF. When administered into the upper third cerebroventricle, TNF 20 ng failed to affect ACTH levels whereas IL-1 30 ng raised ACTH to 638 ± 79 pg/ml compared to 177 ± 24 pg/ml for vehicle (p ≪ 0.001). Furthermore, intraparenchymal injection of IL-1, directly above the median eminence, elevated ACTH to 484 ± 93 pg/ml; again, TNF was completely ineffective. Thus, TNF-α and IL-1β are both potent ACTH secretagogues with complementary modes of action; however, the proximate target of TNF action appears to be peripheral to the CNS and pituitary whereas that of IL-1 appears to be the median eminence.

AB - Tumor necrosis factor-α (TNF) and interleukin-1 β (IL-1) are secreted by activated monocytes and other immune cells. Since IL-1 has been shown to elevate rat plasma ACTH and both of these cytokines induce similar acute-phase responses, the present studies of TNF were undertaken to characterize the ACTH response to this immune cell product. Human rTNF, administered iv at doses (100-1000 ng) which failed to affect blood pressure, food consumption or prolactin levels, resulted in significant peak elevations of rat plasma ACTH within 20 min (mean ± SE 304+94 and 958 ± 128 pg/ml for 100 and 1000 ng, respectively, compared to 53 ± 16 pg/ml for vehicle). rTNF from two different sources produced similar elevations of ACTH as an equivalent amount of rIL-1. TNF failed to affect cultured anterior pituicytes, and it did not modify the response to CRF. When administered into the upper third cerebroventricle, TNF 20 ng failed to affect ACTH levels whereas IL-1 30 ng raised ACTH to 638 ± 79 pg/ml compared to 177 ± 24 pg/ml for vehicle (p ≪ 0.001). Furthermore, intraparenchymal injection of IL-1, directly above the median eminence, elevated ACTH to 484 ± 93 pg/ml; again, TNF was completely ineffective. Thus, TNF-α and IL-1β are both potent ACTH secretagogues with complementary modes of action; however, the proximate target of TNF action appears to be peripheral to the CNS and pituitary whereas that of IL-1 appears to be the median eminence.

UR - http://www.scopus.com/inward/record.url?scp=0024358707&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024358707&partnerID=8YFLogxK

U2 - 10.1210/endo-124-6-3131

DO - 10.1210/endo-124-6-3131

M3 - Article

VL - 124

SP - 3131

EP - 3133

JO - Endocrinology

JF - Endocrinology

SN - 0013-7227

IS - 6

ER -